Clinical Validation

A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
S Paik, S Shak, G Tang, C Kim, J Baker, M Cronin, FL Baehner, MG Walker, D Watson, T Park, W Hiller, ER Fisher, DL Wickerham, J Bryant, N Wolmark
N Engl J Med 2004.351(27):2817-2826.
 
Individualized Care for Patients with Cancer – A Work in Progress
RC Bast, GN Hortobagyi
N Engl J Med 2004.351(27):2865-2867.
 
A Population-Based Study of Tumor Gene Expression and Risk of Breast Cancer Death Among Lymph Node-Negative Patients
LA Habel, S Shak, M Jacobs, A Capra, C Alexander, M Pho, J Baker, MG Walker, D Watson, J Hackett, N Blick, D Greenberg, L Fehrenbacher, B Langholz, CP Quesenberry
Breast Cancer Res 2006.8(3):R25.
 
Gene Expression and Benefit of Chemotherapy in Women with Node-Negative, Estrogen Receptor-Positive Breast Cancer
S Paik, G Tang, S Shak, C Kim, J Baker, W Kim, M Cronin, FL Baehner, D Watson, J Bryant, JP Costantino, C Geyer Jr., DL Wickerham, N Wolmark
J Clin Oncol 2006.24(23):3726-3734.
 
A Step in the Right Direction
S Swain
J Clin Oncol 2006.24(23):3717-3718.
 
Development and Clinical Utility of a 21-Gene Recurrence Score Prognostic Assay in Patients with Early Breast Cancer Treated with Tamoxifen
S Paik
Oncologist 2007.12(6):631-635.
 
The First Report Of The Association Between The Recurrence Score And The Risk Of Recurrence In A Japanese Population
M. Toi, H. Iwata, N. Masuda, S. Ohno, S. Namakura, Y.Yamanaka, T. Nakayama, M. Kashiwaba, S, Kamigaki, K. Aogi, T. Ueno, K. Kuroi.
 
Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study
Dowsett M, Cuzick J, Wales C, Forbes J, Mallon L, Salter J, Quinn E, Bugarini R, Baehner FL, Shak S, on Behalf of the ATAC Trialists Group Royal Marsden Hospital, London, United Kingdom; Wolfson Institute for Preventive Medicine, London, United Kingdom; Newcastle Mater Hospital, Newcastle, Australia; Royal Infirmary, Glasgow,United Kingdom; Genomic Health Institute, Redwood, CA
Abstract # 53
 
Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal, Node-Positive, ER-Positive Breast Cancer
K Albain, W Barlow, S Shak, G Hortobagyi, R Livingston, I Yeh, P Ravdin, C Yoshizawa, FL Baehner, N Davidson, G Sledge, E Winer, C Hudis, J Ingle, E Perez, K Pritchard, L Shepherd, C Allred, K Osborne, D Hayes
Abstract #10: Oral Presentation
 
Prognostic Utility of the 21-Gene Assay Compared with Adjuvant! in Hormone Receptor (HR) Positive Operable Breast Cancer with 0-3 Positive Axillary Nodes Treated with Adjuvant Chemohormonal Therapy (CHT): An Analysis of Intergroup Trial E2197
L Goldstein, P Ravdin, R Gray, C Yoshizawa, B Childs, S Rowley, S Shak, S Badve, FL Baehner, N Davidson, GW Sledge, JA Sparano
Abstract #63: Oral Presentation
 
Prognostic Utility of the 21-Gene Assay in Hormone Receptor (HR)-Positive Operable Breast Cancer and 0-3 Positive Axillary Nodes Treated with Adjuvant Chemohormonal Therapy (CHT): An Analysis of Intergroup Trial E2197
LJ Goldstein, R Gray, B Childs, D Watson, S Rowley, S Shak, S Badve, NE Davidson, GW Sledge, JA Sparano
Abstract #526: Poster Discussion
 
Association Between the 21-Gene Recurrence Score Assay (RS) and Risk of Loco-Regional Failure in Node-Negative, ER-Positive Breast Cancer: Results from NSABP B-14 and NSABP B-20
E Mamounas, G Tang, J Bryant, S Paik, S Shak, JP Costantino, D Watson, DL Wickerham, N Wolmark
Abstract #29: Oral Presentation
 
Expression of the 21 Genes in the Recurrence Score Assay and Tamoxifen Clinical Benefit in the NSABP Study B-14 of Node-Negative, Estrogen Receptor-Positive Breast Cancer
S Paik, S Shak, G Tang, C Kim, J Baker, M Cronin, D Watson, J Bryant, JP Costantino, N Wolmark
Abstract #510: Oral Presentation
 
Gene Expression and Breast Cancer Mortality in Northern California Kaiser Permanente Patients: A Large Population-Based Case Control Study
LA Habel, CP Quesenberry, M Jacobs, D Greenberg, L Fehrenbacher, C Alexander, J Baker, D Watson, J Hackett, S Shak
Abstract #603: Poster Session
 
Expression of the 21 Genes in the Recurrence Score Assay and Prediction of Clinical Benefit from Tamoxifen in NSABP Study B-14 and Chemotherapy in NSABP Study B-20
S Paik, S Shak, G Tang, C Kim, H Joo, J Baker, M Cronin, D Watson, J Bryant, JP Costantino, N Wolmark
Abstract #24: Oral Presentation
 
Risk Classification of Breast Cancer Patients by the Recurrence Score Assay: Comparison to Guidelines Based on Patient Age, Tumor Size, and Tumor Grade
S Paik, S Shak, G Tang, C Kim, J Baker, M Cronin, FL Baehner, MG Walker, D Watson, J Bryant, N Wolmark
Abstract #104: Poster Discussion
 
Multi-Gene RT-PCR Assay for Predicting Recurrence in Node-Negative Breast Cancer Patients NSABP Studies B-20 and B-14
S Paik, S Shak, G Tang, C Kim, J Baker, M Cronin, FL Baehner, MG Walker, DWatson, T Park, W Hiller, ER Fisher, DL Wickerham, J Bryant, N Wolmark
Abstract #16: Oral Presentation
 
Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal, Node-Positive, Estrogen Receptor-Positive Breast Cancer
K Albain, W Barlo, S Shak, G Hortobagyi, R Livingston, I-T Yeh, P Ravdin, R Bugarini, FL Baehner, NE Davidson, GW Sledge, E Winer, C Hudis, J Ingle, E Perez, K Pritchard, L Shepherd, J Gralow, C Yoshizawa, D Allred, C Osborne, D Hayes
Lancet Oncology 2009.10:1016/S1470-2045(09)70314-6.